Costimulatory bispecifics bring new biology to T cell engagers

Two T cell engaging bispecific antibodies may be better than one when it comes to driving activation of T cells against tumors, according to an emerging trend across two of the fall’s major conferences: the American Society of Hematology and Society for Immunotherapy of Cancer. 

In abstracts released ahead of the two conferences, at least seven companies describe costimulatory bispecific or trispecific antibodies that, when paired with traditional CD3-targeting bispecifics, may drive a stronger T cell response...